Definium Therapeutics, Inc. is trading 5.2% down at $21.75 in pre-market as broader risk-off sentiment pressures growth and therapeutics names ahead of key U.S. CPI data.
- The move extends a recent pullback in the stock, tracking lower index futures and global market trends.
- There are no company-specific catalysts or news items driving the current downward price action.
- Growth-oriented sectors are facing increased pressure as investors adopt a cautious stance before the inflation report.